Trial
NCT02974725
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Non-Small Cell Lung Cancer
Intervention
LXH254
Why stopped
Business reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-13